Skip to content

Contact +44 (0) 20 7060 7474 email us

Canada

Canadian Pharmaceutical Market Outlook to 2013

olicy environment, market structure, pipeline analysis, growth opportunities

Publication Date March 2009
Publisher Business Insights
Product Type Report
Pages 136
ISBN Number not applicable
Product Code RBI00196

Price

£2,025.00
approximately: $3,066 | €2,260

pdf

Buy Now

Order above formats by FAX

Order by Fax

Summary

This report provides comprehensive coverage of the Canadian market, incorporating an overview of the country, its socioeconomic status and the epidemiological scenario of major pathophysiological disorders. Furthermore, the report analyzes the scenario in Canada pertaining to pharmaceutical regulation, pricing and reimbursement. Finally, the report analyzes the marketed product portfolios, R&D pipelines and market share data of the leading pharmaceutical companies in Canada, and provides sales forecasts.



Key Findings

  • The Canadian pharma market grew by 13.0% during 2006–07, generating revenues of $16.9bn. The market was driven by the strong growth of cancer and musculoskeletal treatments resulting from the success of novel targeted therapies and the availability of several new high-value biologic treatments.


  • Cardiovascular drug sales accounted for 23.2% of the Canadian pharma market in 2007, accruing
    revenues of $3.9bn. Lipitor remained the market leading statin with sales of $1.0bn in 2007, however the availability of generic simvastatin has resulted in increased therapeutic substitution and reduced sales.


  • Generic drug companies such as Apotex and Novopharm are continuing to demonstrate
    impressive growth, with revenue increases of 26% and 52% respectively in 2007.


  • Pfizer dominated the market with a share of 12.4% in 2007, following sales of $2.1bn. Pfizer’s
    market position was supported by strong sales of Lipitor and Norvasc, which together accounted for
    65.6% of the company’s sales.


  • The Canadian biopharmaceutical industry is facing funding challenges due to administrative and
    tax barriers. These hurdles are forcing companies to partner their innovations with major companies
    prematurely, and they subsequently fail to maximize their revenue potential.


Use this report to...


  • Examine the forecast prevalence of major disorders in the Canadian pharma market over 2009-13 with this report’s analysis of indications including arthritis, asthma, COPD, hypertension, heart diseases, HIV/AIDS, Parkinson’s/Alzheimer’s disease and cancer.

  • Evaluate the policy environment of the Canadian healthcare system with this report’s examination of the latest trends and developments in pharmaceutical regulation, pricing and drug coverage/reimbursement.

  • Assess the competitive landscape of the Canadian pharma market with this report’s analysis of the portfolio sales and therapy area focus of leading manufacturers including AstraZeneca, GSK, J&J, Novartis, Pfizer, Apotex and Novapharm.

  • Predict revenues for currently marketed and pipeline products in the Candian pharma market over 2009-13, with this report’s sales forecasts across major indications, treatment classes and company portfolios.

Contents

  • The Canadian Pharmaceutical Market Outlook to 2013 Executive Summary
  • Overview of Canada
  • Pharmaceutical regulation, pricing and reimbursement
  • Pharmaceutical market structure
  • Pipeline analysis
  • Chapter 1 Scope and methodology
    • Scope
    • Methodology
  • Chapter 2 Overview of Canada
    • Summary
    • Introduction
    • The Canadian economy enters recession
    • An aging Canada
    • Disease burden in Canada - forecast to 2013
    • Arthritis
    • Asthma
    • Chronic obstructive pulmonary disease (COPD)
    • Diabetes
    • Hypertension and heart diseases
    • HIV/AIDS
    • Parkinson's and Alzheimer's disease
    • Cancer
  • Chapter 3 Pharmaceutical regulation,pricing and reimbursement
    • Summary
    • Introduction
    • Pharmaceutical Regulation
    • Intellectual property rights
    • Clinical trial regulation
    • Regulatory submissions and review times
    • Marketing authorization
    • Adverse drug reaction monitoring
    • Pharmaceutical pricing
    • Pricing control policies - an industry perspective
    • Drug coverage and reimbursement
    • Formulary listing
    • Reimbursement
    • Catastrophic drug coverage plan
    • Key trends in regulation, pricing and reimbursement
    • Drug majors unperturbed by the DTCA ban
    • CanWest Mediaworks' legal suit over the DTCA
    • Higher generic drug prices cause concern of rising drug expenditure
    • Introduction of Quebec's maximum price payable policy
    • Compulsory formulary listing leads to irrational pricing in Quebec
    • BC Pharmacare price referencing system unfriendly to branded drugs
    • Pharmaceutical task force offers hope for drug makers in BC
    • Increased co-insurance and deductibles on pharmaceutical consumption
    • COMPUS is likely to usher in a generic prescription era
  • Chapter 4 Pharmaceutical market structure
    • Summary
    • Introduction
    • Pharmaceutical distribution
    • Independent pharmacy distributors (IPD)
    • Self-distributors
    • Retail and hospital pharmacies
    • Independent pharmacies
    • Pharmacy groups
    • Hospital pharmacies
    • Pharmaceutical sales and market analysis
    • Drug sales by province and territory
    • Licensing trends
    • Market analysis by therapeutic area
    • Market analysis by drug classes
    • Market analysis by leading brands
    • Market analysis by key players
    • Branded drug manufacturers
    • Pfizer Canada
    • Sales analysis by therapeutic area
    • Sales analysis of leading brands
    • J&J Canada
    • Sales analysis by therapeutic area
    • Sales analysis of leading brands
    • AstraZeneca Canada
    • Sales analysis by therapeutic area
    • Sales analysis of leading brands
    • GSK Canada
    • Sales analysis by therapeutic area
    • Sales analysis of leading brands
    • Novartis Canada
    • Sales analysis by therapeutic area
    • Sales analysis of leading brands
    • Generic drug manufacturers
    • Apotex Canada
    • Sales analysis by therapeutic area
    • Sales analysis of leading brands
    • Novopharm
    • Sales analysis by therapeutic area
    • Sales analysis of leading brands
    • Canadian biopharmaceutical companies
    • Cangene
    • Product portfolio
    • Pipeline portfolio
    • AEterna Zentaris
    • Product portfolio
    • Pipeline portfolio
    • Canadian market forecast, 2007-2013
    • Market forecast by ATC classes to 2013
    • Market forecast of leading brands to 2013
    • Market forecast of leading companies to 2013
  • Chapter 5 Pipeline analysis
    • Summary
    • Introduction
    • Key pipeline compounds
    • Key pipeline compound of major pharmaceutical companies
    • Telaprevir
    • Isentress
    • Prevnar 13vPnC
    • Cervarix
    • Menveo
    • Effient
    • Xarelto
    • Multaq
    • Onglyza
    • Actemra
    • Denosumab
    • Vimpat
    • Telcagepant
    • Axitinib
    • Ixempra
    • Key pipeline compounds of Canadian biopharmaceutical companies
    • Overview of issues encountered by the biopharmaceutical industry
    • Urocidin
    • DM-71
    • Dirucotide
    • Voclosporin
    • Tesamorelin
    • Market forecast of pipeline compounds to 2013
  • Chapter 6 Appendix
    • IMS Data
    • Anatomical Therapeutic Classification (ATC)
    • C: Cardiovascular system
    • N: Nervous system
    • A: Alimentary tract and metabolism
    • L: Antineoplastic and immunomodulating agents
    • J: General anti-infectives systemic
    • R: Respiratory system
    • M: Musculo-skeletal system
    • G: Genito-urinary system and sex hormones
    • B: Blood and blood forming organs
    • D: Dermatologicals
    • T: Diagnostic agents
    • H: Systemic hormonal preparations
    • S: Sensory organs
    • V: Various
    • Licensing status as per IMS Health
    • Original brand
    • Other brand
    • Licensed brand
    • Patent N/A brands
    • Unbranded/generic product
    • Glossary
    • Index
  • List of Figures
    • Figure 3.1: Overview of regulation of access to drugs in Canada
    • Figure 3.2: Clinical trial regulations governed by the TPD
    • Figure 3.3: Reimbursement process
    • Figure 3.4: Formulary listing
    • Figure 4.5: Pharmaceutical sales by provinces and territories, 2006-2007
    • Figure 4.6: Sales of types of brands in Canada, 2006-2007
    • Figure 4.7: Competitive analysis of Canadian market by leading therapeutic areas, 2006-2007
    • Table 2.1: Socioeconomic indicators, 2007
    • Table 2.2: Demographic indicators, 2007
    • Table 2.3: Forecast epidemiology in Canada
    • Table 3.4: Different forms of regulatory submission in Canada
    • Table 3.5: Review times of major drugs approved after January 2005
    • Table 3.6: PMPRB drug categories
    • Table 4.7: Canadian market by therapeutic area, 2006-2007
    • Table 4.8: Leading drug classes in the Canadian market, 2006-2007
    • Table 4.9: Leading brands in the Canadian market, 2006-2007
    • Table 4.10: Key players in the Canadian market, 2006-2007
    • Table 4.11: Ranking of companies across ATC classes in Canada by sales 2007 ($m)
    • Table 4.12: Pfizer sales by therapeutic areas, 2006-2007
    • Table 4.13: Leading brands of Pfizer, 2006-2007
    • Table 4.14: J&J sales by therapeutic areas, 2006-2007
    • Table 4.15: Leading brands of J&J, 2006-2007
    • Table 4.16: AstraZeneca sales by therapeutic areas, 2006-2007
    • Table 4.17: Leading brands of AstraZeneca, 2006-2007
    • Table 4.18: GlaxoSmithKline sales by therapeutic areas, 2006-2007
    • Table 4.19: Leading brands of GlaxoSmithKline, 2006-2007
    • Table 4.20: Novartis sales by therapeutic areas, 2006-2007
    • Table 4.21: Leading brands of Novartis, 2006-2007
    • Table 4.22: Apotex sales by therapeutic areas, 2006-2007
    • Table 4.23: Leading brands of Apotex, 2006-2007
    • Table 4.24: Novopharm sales by therapeutic areas, 2006-2007
    • Table 4.25: Leading brands of Novopharm, 2006-2007
    • Table 4.26: Pipeline portfolio of Cangene
    • Table 4.27: Pipeline portfolio of AEterna Zentaris
    • Table 4.28: ATC sales forecast, 2008-13
    • Table 4.29: Leading brands sales forecast, 2008-13
    • Table 4.30: ATC sales forecast, 2008-13
    • Table 5.31: An overview of telaprevir
    • Table 5.32: An overview of Isentress
    • Table 5.33: An overview of Prevnar 13vPnC
    • Table 5.34: An overview of Cervarix
    • Table 5.35: An overview of Menveo
    • Table 5.36: An overview of Effient
    • Table 5.37: An overview of Xarelto
    • Table 5.38: An overview of Multaq
    • Table 5.39: An overview of Onglyza
    • Table 5.40: An overview of Actemra
    • Table 5.41: An overview of denosumab
    • Table 5.42: An overview of Vimpat
    • Table 5.43: An overview of Telcagepant
    • Table 5.44: Results of Phase III trial of telcagepant in migraine
    • Table 5.45: An overview of axitinib
    • Table 5.46: An overview of Ixempra
    • Table 5.47: An overview of Urocidin
    • Table 5.48: An overview of DM-71
    • Table 5.49: An overview of Dirucotide
    • Table 5.50: An overview of voclosporin
    • Table 5.51: An overview of Tesamorelin
    • Table 5.52: Pipeline sales forecast, 2008-13